OR

EQS-News: Offer Update Announcement

Retrieved on: 
Sunday, December 10, 2023
Dividend, Relevant, Growth, EUR, Condition, PRA, RNS, London, Communication, Internet, Uncertainty, Person, FDI, Tax, Documentation, Censorship of LGBT issues, Prudential regulation, Finance, Competition, OR, SAME, GBP, Settlement, Financial Conduct Authority, Nature, Condition precedent, Trustee, Legislation, Bidding, Bloomberg, London Stock Exchange, Risk, Financial services, Telephone, Email, United Kingdom, FCA, Security (finance), Property management, Auction, Financial adviser, Cryptocurrency, NEW ZEALAND, Citigroup

Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in the offer document which will be published shortly before the commencement of the acceptance period under the Offer.

Key Points: 
  • Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in the offer document which will be published shortly before the commencement of the acceptance period under the Offer.
  • This announcement constitutes the Final Results Announcement for the purposes of the Offer Document.
  • In accordance with Section 5.5 of the Offer Document, Settlement of the Offer will take place on or around 10 Trading Days after the date of this announcement.
  • Capitalised terms in this announcement, unless otherwise defined, have the same meanings as set out in the Offer Document.

EQS-News: Satisfaction of Regulatory Clearance Condition

Retrieved on: 
Wednesday, December 6, 2023
2003 IAAF World Athletics Final – Results, Finance, Legislation, Prudential Regulation Authority (United Kingdom), Financial Conduct Authority, Condition precedent, London Stock Exchange, Censorship of LGBT issues, Communication, Nature, Email, Competition, Growth, RNS, Order of precedence, Trustee, PRA, Relevant, SAME, Article, Internet, FDI, Financial Services and Markets Act 2000, Telephone, OR, Documentation, AFRICA, Risk, Settlement, FCA, Uncertainty, Person, GBP, Security (finance), Property management, Auction, Financial adviser, Medical device, Bidding, NEW ZEALAND, Citigroup

The Bidder refers to the Condition Precedent set out in in Section 4.1.1 of the Offer Document, as amended by the announcement made on 29 September 2023, relating to the receipt of the Competition and FDI Approvals (the "Regulatory Clearance Condition").

Key Points: 
  • The Bidder refers to the Condition Precedent set out in in Section 4.1.1 of the Offer Document, as amended by the announcement made on 29 September 2023, relating to the receipt of the Competition and FDI Approvals (the "Regulatory Clearance Condition").
  • The Bidder confirms that all Relevant Competition Authorities and that all Relevant FDI Authorities have provided the requisite clearance for the settlement of the Offer and that the Regulatory Clearance Condition is satisfied.
  • Assuming the satisfaction (or waiver by the Bidder) of all Conditions Precedent by such date, Settlement is expected to begin by no later than on or around 13 December 2023.
  • Capitalised terms in this announcement, unless otherwise defined, have the same meanings as set out in the Offer Document.

Update on Cost Reduction Plan and Completion of the Firm Placing

Retrieved on: 
Tuesday, December 5, 2023
European Union (Withdrawal) Act 2018, Automation, ANY, Metrobank, Element, Bank Holding Company Act, LSE, IT, OR, London Stock Exchange Group, FCA, Growth, Official List, Financial Conduct Authority, AFRICA, Environment, Cryptocurrency, Bank, Security (finance), EU

After further evaluation of the cost base, Metro Bank has now identified potential cost savings of up to £50 million per year.

Key Points: 
  • After further evaluation of the cost base, Metro Bank has now identified potential cost savings of up to £50 million per year.
  • The cost reduction plan will support Metro Bank in taking advantage of this opportunity.
  • The £150 million of new equity was structured as a firm placing of 500,000,000 new ordinary shares at an issue price of 30 pence per new ordinary share (the “Firm Placing”).
  • On 27 November 2023, the Company announced the passing of the shareholder resolutions necessary to approve the Firm Placing.

Hanzo Unveils Spotlight AI, First Solution for Automated Relevancy Assessment

Retrieved on: 
Thursday, November 9, 2023
ChatGPT, Architecture, Watson, Data science, OR, API, Illuminate, Trust, GA, Hattori Hanzō, AI, Collection, IBM, General counsel, Software as a service, Medical device

Leveraging trustworthy AI, Hanzo has achieved 95% recall in pinpointing pertinent documents to a case, transforming a once arduous manual task into a swift, automated process.

Key Points: 
  • Leveraging trustworthy AI, Hanzo has achieved 95% recall in pinpointing pertinent documents to a case, transforming a once arduous manual task into a swift, automated process.
  • Spotlight AI is a secured solution that leverages IBM’s data science and machine learning studio (previously known as Watson studio, now a part of watsonx.ai )and seamlessly integrates with Illuminate, presenting a powerful yet user-friendly automated relevancy assessment tool.
  • "Hanzo has identified a very important challenge that legal teams face today regarding early assessment and relevancy for legal matters.
  • Hanzo is gathering critical insight from pre-release customers to help refine Spotlight AI models to further scale to enterprise content levels.

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

Retrieved on: 
Thursday, November 9, 2023
Health policy, Policy, OH, MDD, TMS, STIM, Blue Cross Blue Shield Association, HI, Neuronetics, Major depressive disorder, DSM-IV codes, Psychotherapy, Criterion, OR, Quality of life, Marketing, Aetna, Transcranial magnetic stimulation, BCBS, SSM Health, CO, Patient, Regenerative Medicine Advanced Therapy, Pharmaceutical industry, Health insurance, Ferdinand Magellan, UnitedHealth Group, MD

Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.

Key Points: 
  • Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.
  • The policy updates from BCBS Kansas City and Dean Health Plan are effective immediately, with the Magellan update going into effect on November 18, 2023.
  • Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy changes.
  • For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Research, PRS, Carboplatin, Ovarian cancer, Trae Waynes, Traveller Alien Module 2: K'kree, Oncology nursing, Partnership, CBR, September 5, ATR, CCNE1, Circulating tumor DNA, OR, BMS, Paclitaxel, Ono, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Glomus tumor, Roche, Net, Safety, Therapy, Cancer, Patient, DNA, MRR, Conference, Clinical trial, Anemia, IST, AACR, Red Barricades: ASL Historical Module 1, FOLFIRI, Genotype, PPP2R1A, PKMYT1, FBXW7, Princess Margaret Cancer Centre, RECIST, Modularity, PARP, Pharmaceutical industry, Vaccine, Reinsurance, Reparenting, G&A, IND

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

FIBRA Macquarie México Announces Ordinary and Extraordinary Holders’ Meeting

Retrieved on: 
Thursday, November 9, 2023
Commercial Building & Real Estate, Construction & Property, REIT, ACT, Agenda, Attention, Macquarie Group, Treasury, Global Certification Commission, Av, Meeting, Trustee, Eric Holder, II, Telephone, Publication, Business analyst, Deposit Insurance and Credit Guarantee Corporation, Commonwealth, AS, OR, Trust, Mexican Stock Exchange, Paseo de la Reforma, City, Risk, Common, RNV, BMV, AND, S.A, Medical device, Security (finance)

The Call Notice and materials to be presented at the Meeting will be available in FIBRA Macquarie’s website at www.fibramacquarie.com .

Key Points: 
  • The Call Notice and materials to be presented at the Meeting will be available in FIBRA Macquarie’s website at www.fibramacquarie.com .
  • FIBRA Macquarie México (FIBRA Macquarie) (BMV:FIBRAMQ) is a real estate investment trust (fideicomiso de inversión en bienes raíces), or FIBRA, listed on the Mexican Stock Exchange (Bolsa Mexicana de Valores) targeting industrial, retail and office real estate opportunities in Mexico, with a primary focus on stabilized income-producing properties.
  • The obligations of these other Macquarie Group entities do not represent deposits or other liabilities of Macquarie Bank.
  • Macquarie Bank does not guarantee or otherwise provide assurance in respect of the obligations of these other Macquarie Group entities.

Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds

Retrieved on: 
Wednesday, November 8, 2023
FOR, J. P. Morgan, EBITDA, Person, Mizuho, NOT, OR, BNP Paribas, KID, Linklaters, BBB, Media release, S&P, AND, CHF, Security (finance), Bank, Novartis, BAA2, EUR, EEA

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Key Points: 
  • NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
    Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 million
    Basel, November 8, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of three highly successful inaugural Eurobonds, with total gross proceeds of EUR 2.0 billion.
  • Following a debut transaction in CHF last month, this issuance marks the entry of Sandoz into the EUR debt capital market.
  • Colin Bond, Sandoz CFO said: "These inaugural bonds represent a further milestone for Sandoz, establishing us firmly as a new issuer in the EUR bond market and creating a diversified and well-balanced financing profile from a currency and maturity perspective."
  • The proceeds, together with those from last month’s CHF issuance, will be used for the repayment of the EUR 2.4 billion bridge loan and for general corporate purposes.

Johnson & Johnson MedTech Provides Details and Timeline for General Surgery Robot

Retrieved on: 
Tuesday, November 7, 2023
Digital, Science, FDA, Minimally invasive procedure, Robotics, General surgery, University, OR, IDE, Large intestine, ORS, Surgeon, Palm Beach, Ethicon, Freedom, Workflow, Safety, Movement, Johnson & Johnson, Patient, Pharmaceutical industry, Dentistry, Medical device

NEW BRUNSWICK, N.J., Nov. 7, 2023 /PRNewswire/ -- Johnson & Johnson MedTech* today announced plans to submit the OTTAVA robotic surgical system for an investigational device exemption (IDE) application to the U.S. Food & Drug Administration (FDA) in the second half of 2024 to initiate clinical trials.

Key Points: 
  • Drawing on Johnson & Johnson MedTech's more than 135-year legacy of leadership in surgery, OTTAVA reimagines the surgical experience.
  • "Johnson & Johnson was born in surgery with the advent of sterile sutures, and we have since helped surgeons improve care for patients by offering transformative technologies across all types of surgery," said Hani Abouhalka, Company Group Chairman, Robotics & Digital, Johnson & Johnson MedTech.
  • Ethicon instruments on OTTAVA are backed by decades of innovation and market leadership in minimally invasive surgery, providing leading device-to-tissue and user-to-device interactions.
  • The OTTAVA robotic system is under development and is not authorized to be marketed or sold in any market.

Black Rock Coffee Bar Unveils its 2023 Winter Drink Menu for the Holiday Season

Retrieved on: 
Tuesday, October 31, 2023
Sun Belt, Old Town, Holiday, Privately held company, Coffee, Vanilla, Fastest, Milk, FUEL, OR, Inc., ID, CO, Peppermint bark, Pacific Northwest

Portland, Oregon, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, a national boutique coffee chain, has announced its winter drink menu for the 2023 holiday season, available at all 100-plus store locations across seven states, including OR, WA, AZ, CA, ID, CO, and TX.

Key Points: 
  • Portland, Oregon, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, a national boutique coffee chain, has announced its winter drink menu for the 2023 holiday season, available at all 100-plus store locations across seven states, including OR, WA, AZ, CA, ID, CO, and TX.
  • This year, Black Rock Coffee Bar presents a delightful array of Winter Wonder beverages, available in iced, hot or blended options.
  • Following is Black Rock Coffee Bar’s winter lineup:
    Peppermint Bark White Mocha – This refreshing and spirit-lifting drink is an absolute fan favorite during the winter season.
  • In 2023, Black Rock Coffee Bar ranked 1179th among America’s Fastest-Growing Private Companies by Inc. Magazine’s 5000 Annual List.